Company Filing History:
Years Active: 2012
Title: David H A Jones: Innovator in Recombinant Technology
Introduction
David H A Jones is a notable inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the production of immunoglobulin A (IgA) through recombinant methods. His innovative work has implications for therapeutic applications and advances in medical research.
Latest Patents
David H A Jones holds a patent for the "Efficient production of IgA in recombinant mammalian cells." This invention provides an immortalized human retina cell that expresses E1A and E1B proteins of an adenovirus. The cell contains recombinant nucleic acid encoding an IgA molecule in an expressible format. Additionally, the patent outlines a method for the recombinant production of an IgA molecule, which involves culturing a cell of the invention and expressing the recombinant nucleic acid encoding the IgA.
Career Highlights
David H A Jones is associated with Crucell Holland B.V., a company known for its focus on biopharmaceuticals and vaccine development. His work at Crucell has allowed him to explore innovative solutions in the field of recombinant technology. With a patent portfolio that includes 1 patent, he continues to contribute to advancements in biotechnology.
Collaborations
David has collaborated with various professionals in his field, including his coworker Abraham Bout. Their combined expertise enhances the research and development efforts at Crucell Holland B.V.
Conclusion
David H A Jones exemplifies the spirit of innovation in biotechnology through his patented work on IgA production. His contributions are paving the way for future advancements in medical therapies and research.